Responsible for operational management of projects concerning development and clinical application of innovative pharmaceuticals in the field of immune-oncology. Current products under investigation are Dendritic Cell Therapy, Oncolytic Viruses, and Neoantigen Peptides.

Head of Production for Cell and Gene Therapy. Products under investigation were autologous Dendritic Cells, CAR-T cells, TCR engineered T-cells, oncolytic viruses, and neoantigen peptides for treatment of several cancer types, i.e. mesothelioma, pancreatic cancer, and melanoma. Responsible for operational management of the manufacturing facility, responsible for managing day-to-day operations of 8-10 operators who developed, characterized, validated, produced, and quality controlled these products. Responsible for guidance of investigators in making their production processes GMP compliant and efficiently translate these products to the clinic.

Projects:1. Phase 1 clinical trial: Dendritic Cell Immunotherapy as treatment for Malignant Mesothelioma patients2. The role of Macrophages in the development of human Malignant Mesothelioma. 3. Immunomonitoring analysis in Lung Cancer patients.

MesoPher (Dendritic Cell Therapy) product expert.Set-up of CMC (Module 3) part of Market Authorisation dossier. Performance of investigative research studies to further develop and characterize MesoPher.Quality by Design analysis of MesoPher.

Project: Discovering the key role of differentially expressed (new) miRNA's in suptypes of pediatric precursor B-cell leukemia.

Project: Performance of RPPA (Reverse Phase Protein Array) and Laser Capture Microdissection

Project: The role of CtBP1 in human epithelial differentiation and tumor formation in the intestine.